Linear Mixed Effect Models for Bone Turnover Markers in Patients With Active CID Receiving Infliximab Induction Therapy
| bsALPa | P1NP | CTx | TRAcP 5b | |
| μg/L | μg/L | ng/L | U/L | |
| Group median (IQR) | ||||
| Non responder | ||||
| Baseline | 8.3 (7.2, 9.0) | 21.5 (19.5, 26.0) | 813 (750, 824) | 5.3 (5.1, 5.5) |
| Week 1 | 6.8 (6.6, 7.7) | 28.8 (19.9, 33.6) | 739 (686, 821) | 5.2 (4.9, 5.7) |
| Week 2 | 7.2 (6.0, 8.7) | 27.3 (26.4, 32.3) | 742 (592, 847) | 5.0 (4.5, 5.3) |
| Week 6 | 7.5 (5.9, 10.5) | 20.0 (16.4, 27.4) | 618 (567, 687) | 5.3 (4.5, 6.0) |
| Week 8 | 7.3 (6.7, 8.2) | 18.5 (15.6, 23.6) | 664 (589, 814) | 5.3 (4.9, 5.6) |
| Responder | ||||
| Baseline | 7.9 (7.2, 8.3) | 22.5 (20.0, 38.0) | 657 (618, 839) | 5.1 (4.4, 5.4) |
| Week 1 | 7.6 (7.2, 8.4) | 29.8 (27.6, 34.5) | 606 (522, 816) | 4.2 (3.8, 4.4) |
| Week 2 | 7.8 (7.1, 9.3) | 23.0 (20.4, 38.9) | 480 (419, 680) | 3.9 (3.4, 4.0) |
| Week 6 | 10.5 (8.5, 12.6) | 34.7 (29.4, 40.5) | 607 (584, 672) | 4.2 (4.0, 4.4) |
| Week 8 | 13.3 (11.9, 17.3) | 35.6 (33.8, 50.5) | 640 (577, 738) | 4.5 (4.2, 4.6) |
| Between group coefficient estimateb | ||||
| Week 1 | 0.5 (−1.8, 3.7) | −0.8 (−9.6, 7.9) | −36.8 (−231.9, 158.4) | −0.9* (−1.7, −0.2) |
| Week 2 | 0.6 (−1.7, 3.8) | −5.5 (−14.3, 3.2) | −84.1 (−279.4, 111.2) | −1.0* (−1.7, −0.2) |
| Week 6 | 2.4 (−0.4, 6.4) | 8.2 (−0.6, 16.9) | 97.6 (−97.9, 293.1) | −0.8* (−1.6, −0.1) |
| Week 8 | 6.4** (2.5, 11.9) | 16.8** (8.1, 25.6) | 27.7 (−168.1, 223.5) | −0.5 (−1.2, 0.3) |
| Coefficient estimate versus baseline for responder group onlyc | ||||
| Week 1 | −0.5 (−1.9, 1.2) | 3.2 (−1.5, 7.8) | −70.4 (−209.1, 68.3) | −0.9** (−1.4, −0.4) |
| Week 2 | −0.3 (−1.8, 1.4) | 1.1 (−3.6, 5.7) | −152.2* (−291.1, −13.4) | −1.3** (−1.8, −0.8) |
| Week 6 | 2.2* (0.4, 4.6) | 7.3** (2.6, 12.0) | −62.8 (−201.8, 76.3) | −0.8** (−1.3, −0.3) |
| Week 8 | 5.5** (3.0, 8.5) | 13.7** (9.0, 18.4) | −58.4 (−197.9, 81.1) | −0.5 (−1.0, 0.0) |
| bsALPa | P1NP | CTx | TRAcP 5b | |
| μg/L | μg/L | ng/L | U/L | |
| Group median (IQR) | ||||
| Non responder | ||||
| Baseline | 8.3 (7.2, 9.0) | 21.5 (19.5, 26.0) | 813 (750, 824) | 5.3 (5.1, 5.5) |
| Week 1 | 6.8 (6.6, 7.7) | 28.8 (19.9, 33.6) | 739 (686, 821) | 5.2 (4.9, 5.7) |
| Week 2 | 7.2 (6.0, 8.7) | 27.3 (26.4, 32.3) | 742 (592, 847) | 5.0 (4.5, 5.3) |
| Week 6 | 7.5 (5.9, 10.5) | 20.0 (16.4, 27.4) | 618 (567, 687) | 5.3 (4.5, 6.0) |
| Week 8 | 7.3 (6.7, 8.2) | 18.5 (15.6, 23.6) | 664 (589, 814) | 5.3 (4.9, 5.6) |
| Responder | ||||
| Baseline | 7.9 (7.2, 8.3) | 22.5 (20.0, 38.0) | 657 (618, 839) | 5.1 (4.4, 5.4) |
| Week 1 | 7.6 (7.2, 8.4) | 29.8 (27.6, 34.5) | 606 (522, 816) | 4.2 (3.8, 4.4) |
| Week 2 | 7.8 (7.1, 9.3) | 23.0 (20.4, 38.9) | 480 (419, 680) | 3.9 (3.4, 4.0) |
| Week 6 | 10.5 (8.5, 12.6) | 34.7 (29.4, 40.5) | 607 (584, 672) | 4.2 (4.0, 4.4) |
| Week 8 | 13.3 (11.9, 17.3) | 35.6 (33.8, 50.5) | 640 (577, 738) | 4.5 (4.2, 4.6) |
| Between group coefficient estimateb | ||||
| Week 1 | 0.5 (−1.8, 3.7) | −0.8 (−9.6, 7.9) | −36.8 (−231.9, 158.4) | −0.9* (−1.7, −0.2) |
| Week 2 | 0.6 (−1.7, 3.8) | −5.5 (−14.3, 3.2) | −84.1 (−279.4, 111.2) | −1.0* (−1.7, −0.2) |
| Week 6 | 2.4 (−0.4, 6.4) | 8.2 (−0.6, 16.9) | 97.6 (−97.9, 293.1) | −0.8* (−1.6, −0.1) |
| Week 8 | 6.4** (2.5, 11.9) | 16.8** (8.1, 25.6) | 27.7 (−168.1, 223.5) | −0.5 (−1.2, 0.3) |
| Coefficient estimate versus baseline for responder group onlyc | ||||
| Week 1 | −0.5 (−1.9, 1.2) | 3.2 (−1.5, 7.8) | −70.4 (−209.1, 68.3) | −0.9** (−1.4, −0.4) |
| Week 2 | −0.3 (−1.8, 1.4) | 1.1 (−3.6, 5.7) | −152.2* (−291.1, −13.4) | −1.3** (−1.8, −0.8) |
| Week 6 | 2.2* (0.4, 4.6) | 7.3** (2.6, 12.0) | −62.8 (−201.8, 76.3) | −0.8** (−1.3, −0.3) |
| Week 8 | 5.5** (3.0, 8.5) | 13.7** (9.0, 18.4) | −58.4 (−197.9, 81.1) | −0.5 (−1.0, 0.0) |
CID = chronic inflammatory diseases; bsALP = bone specific alkaline phosphatase; P1NP = procollagen type 1 N terminal propeptide; CTx = C terminal telopeptide; TRAcP 5b = tartrate resistant acid phosphatase 5b; IQR = interquartile range.
Table shows group median (IQR) or mixed effects model coefficient (95% confidence interval).
Week 0 and non responder group used as reference groups for each model.
bsALP was naturally log transformed before fitting regression models to ensure normal distribution of residuals. Estimates have been back transformed for ease of interpretation.
Coefficient estimate is for responder group compared with non responder group.
Coefficient estimate is for categorical time compared with baseline for models fitted to responder group only.
p < 0.05.
p < 0.01.
Linear Mixed Effect Models for Bone Turnover Markers in Patients With Active CID Receiving Infliximab Induction Therapy
| bsALPa | P1NP | CTx | TRAcP 5b | |
| μg/L | μg/L | ng/L | U/L | |
| Group median (IQR) | ||||
| Non responder | ||||
| Baseline | 8.3 (7.2, 9.0) | 21.5 (19.5, 26.0) | 813 (750, 824) | 5.3 (5.1, 5.5) |
| Week 1 | 6.8 (6.6, 7.7) | 28.8 (19.9, 33.6) | 739 (686, 821) | 5.2 (4.9, 5.7) |
| Week 2 | 7.2 (6.0, 8.7) | 27.3 (26.4, 32.3) | 742 (592, 847) | 5.0 (4.5, 5.3) |
| Week 6 | 7.5 (5.9, 10.5) | 20.0 (16.4, 27.4) | 618 (567, 687) | 5.3 (4.5, 6.0) |
| Week 8 | 7.3 (6.7, 8.2) | 18.5 (15.6, 23.6) | 664 (589, 814) | 5.3 (4.9, 5.6) |
| Responder | ||||
| Baseline | 7.9 (7.2, 8.3) | 22.5 (20.0, 38.0) | 657 (618, 839) | 5.1 (4.4, 5.4) |
| Week 1 | 7.6 (7.2, 8.4) | 29.8 (27.6, 34.5) | 606 (522, 816) | 4.2 (3.8, 4.4) |
| Week 2 | 7.8 (7.1, 9.3) | 23.0 (20.4, 38.9) | 480 (419, 680) | 3.9 (3.4, 4.0) |
| Week 6 | 10.5 (8.5, 12.6) | 34.7 (29.4, 40.5) | 607 (584, 672) | 4.2 (4.0, 4.4) |
| Week 8 | 13.3 (11.9, 17.3) | 35.6 (33.8, 50.5) | 640 (577, 738) | 4.5 (4.2, 4.6) |
| Between group coefficient estimateb | ||||
| Week 1 | 0.5 (−1.8, 3.7) | −0.8 (−9.6, 7.9) | −36.8 (−231.9, 158.4) | −0.9* (−1.7, −0.2) |
| Week 2 | 0.6 (−1.7, 3.8) | −5.5 (−14.3, 3.2) | −84.1 (−279.4, 111.2) | −1.0* (−1.7, −0.2) |
| Week 6 | 2.4 (−0.4, 6.4) | 8.2 (−0.6, 16.9) | 97.6 (−97.9, 293.1) | −0.8* (−1.6, −0.1) |
| Week 8 | 6.4** (2.5, 11.9) | 16.8** (8.1, 25.6) | 27.7 (−168.1, 223.5) | −0.5 (−1.2, 0.3) |
| Coefficient estimate versus baseline for responder group onlyc | ||||
| Week 1 | −0.5 (−1.9, 1.2) | 3.2 (−1.5, 7.8) | −70.4 (−209.1, 68.3) | −0.9** (−1.4, −0.4) |
| Week 2 | −0.3 (−1.8, 1.4) | 1.1 (−3.6, 5.7) | −152.2* (−291.1, −13.4) | −1.3** (−1.8, −0.8) |
| Week 6 | 2.2* (0.4, 4.6) | 7.3** (2.6, 12.0) | −62.8 (−201.8, 76.3) | −0.8** (−1.3, −0.3) |
| Week 8 | 5.5** (3.0, 8.5) | 13.7** (9.0, 18.4) | −58.4 (−197.9, 81.1) | −0.5 (−1.0, 0.0) |
| bsALPa | P1NP | CTx | TRAcP 5b | |
| μg/L | μg/L | ng/L | U/L | |
| Group median (IQR) | ||||
| Non responder | ||||
| Baseline | 8.3 (7.2, 9.0) | 21.5 (19.5, 26.0) | 813 (750, 824) | 5.3 (5.1, 5.5) |
| Week 1 | 6.8 (6.6, 7.7) | 28.8 (19.9, 33.6) | 739 (686, 821) | 5.2 (4.9, 5.7) |
| Week 2 | 7.2 (6.0, 8.7) | 27.3 (26.4, 32.3) | 742 (592, 847) | 5.0 (4.5, 5.3) |
| Week 6 | 7.5 (5.9, 10.5) | 20.0 (16.4, 27.4) | 618 (567, 687) | 5.3 (4.5, 6.0) |
| Week 8 | 7.3 (6.7, 8.2) | 18.5 (15.6, 23.6) | 664 (589, 814) | 5.3 (4.9, 5.6) |
| Responder | ||||
| Baseline | 7.9 (7.2, 8.3) | 22.5 (20.0, 38.0) | 657 (618, 839) | 5.1 (4.4, 5.4) |
| Week 1 | 7.6 (7.2, 8.4) | 29.8 (27.6, 34.5) | 606 (522, 816) | 4.2 (3.8, 4.4) |
| Week 2 | 7.8 (7.1, 9.3) | 23.0 (20.4, 38.9) | 480 (419, 680) | 3.9 (3.4, 4.0) |
| Week 6 | 10.5 (8.5, 12.6) | 34.7 (29.4, 40.5) | 607 (584, 672) | 4.2 (4.0, 4.4) |
| Week 8 | 13.3 (11.9, 17.3) | 35.6 (33.8, 50.5) | 640 (577, 738) | 4.5 (4.2, 4.6) |
| Between group coefficient estimateb | ||||
| Week 1 | 0.5 (−1.8, 3.7) | −0.8 (−9.6, 7.9) | −36.8 (−231.9, 158.4) | −0.9* (−1.7, −0.2) |
| Week 2 | 0.6 (−1.7, 3.8) | −5.5 (−14.3, 3.2) | −84.1 (−279.4, 111.2) | −1.0* (−1.7, −0.2) |
| Week 6 | 2.4 (−0.4, 6.4) | 8.2 (−0.6, 16.9) | 97.6 (−97.9, 293.1) | −0.8* (−1.6, −0.1) |
| Week 8 | 6.4** (2.5, 11.9) | 16.8** (8.1, 25.6) | 27.7 (−168.1, 223.5) | −0.5 (−1.2, 0.3) |
| Coefficient estimate versus baseline for responder group onlyc | ||||
| Week 1 | −0.5 (−1.9, 1.2) | 3.2 (−1.5, 7.8) | −70.4 (−209.1, 68.3) | −0.9** (−1.4, −0.4) |
| Week 2 | −0.3 (−1.8, 1.4) | 1.1 (−3.6, 5.7) | −152.2* (−291.1, −13.4) | −1.3** (−1.8, −0.8) |
| Week 6 | 2.2* (0.4, 4.6) | 7.3** (2.6, 12.0) | −62.8 (−201.8, 76.3) | −0.8** (−1.3, −0.3) |
| Week 8 | 5.5** (3.0, 8.5) | 13.7** (9.0, 18.4) | −58.4 (−197.9, 81.1) | −0.5 (−1.0, 0.0) |
CID = chronic inflammatory diseases; bsALP = bone specific alkaline phosphatase; P1NP = procollagen type 1 N terminal propeptide; CTx = C terminal telopeptide; TRAcP 5b = tartrate resistant acid phosphatase 5b; IQR = interquartile range.
Table shows group median (IQR) or mixed effects model coefficient (95% confidence interval).
Week 0 and non responder group used as reference groups for each model.
bsALP was naturally log transformed before fitting regression models to ensure normal distribution of residuals. Estimates have been back transformed for ease of interpretation.
Coefficient estimate is for responder group compared with non responder group.
Coefficient estimate is for categorical time compared with baseline for models fitted to responder group only.
p < 0.05.
p < 0.01.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
